Mentice AB (OSTO:MNTC) Return-on-Tangible-Asset: -1.83% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MNTC Mentice AB OSTO:MNTC
72 GF Score
Price kr14.95
GF Value kr23.96
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Mentice AB Return-on-Tangible-Asset?

Mentice AB OSTO:MNTC +1.36% 72 Return-on-Tangible-Asset is -1.83% as of Jun. 2026. GuruFocus rates OSTO:MNTC with a GF Score™ of 72/100 and a GF Value™ of kr23.96 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Mentice AB ranks worse than 56.09% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Mentice AB's annualized Net Income for the quarter that ended in Jun. 2026 was kr-3.5 Mil. Mentice AB's average total tangible assets for the quarter that ended in Jun. 2026 was kr192.6 Mil. Therefore, Mentice AB's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -1.83%.

The historical rank and industry rank for Mentice AB's Return-on-Tangible-Asset or its related term are showing as below:

OSTO:MNTC' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -19.47   Med: -8.95   Max: 24.46
Current: -2.54

During the past 9 years, Mentice AB's highest Return-on-Tangible-Asset was 24.46%. The lowest was -19.47%. And the median was -8.95%.

OSTO:MNTC's Return-on-Tangible-Asset is ranked worse than
56.09% of 854 companies
in the Medical Devices & Instruments industry
Industry Median: 0.735 vs OSTO:MNTC: -2.54

Mentice AB  (OSTO:MNTC) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Mentice AB Return-on-Tangible-Asset Related Terms


Mentice AB Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Mentice AB's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mentice AB Return-on-Tangible-Asset Chart

Mentice AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only -19.47 -17.11 -1.38 -8.95 -15.78

Mentice AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.13 -0.67 28.19 -33.35 -1.83

OSTO:MNTC vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison

For the Medical Devices subindustry, Mentice AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mentice AB Return-on-Tangible-Asset vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Mentice AB's Return-on-Tangible-Asset falls into.


OSTO:MNTC
72GF Score
Mentice AB OSTO:MNTC
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mentice AB Return-on-Tangible-Asset Calculation

Mentice AB's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-32.334/( (206.796+202.994)/ 2 )
=-32.334/204.895
=-15.78 %

Mentice AB's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-3.52/( (192.093+193.107)/ 2 )
=-3.52/192.6
=-1.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2026) net income data.

What does a Return-on-Tangible-Asset of -1.83% mean?
Mentice AB (OSTO:MNTC) has a Return-on-Tangible-Asset of -1.83% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mentice AB and its competitors. According to the industry distribution chart, Mentice AB ranks #479 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 56.1%.
Is Mentice AB's Return-on-Tangible-Asset too high?
Mentice AB's current Return-on-Tangible-Asset is -1.83%. Based on the distribution chart, Mentice AB ranks #479 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Mentice AB has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #479 out of 854 companies for Return-on-Tangible-Asset. This places Mentice AB in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.74, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current Return-on-Tangible-Asset is -1.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (OSTO:MNTC) is currently considered Significantly Undervalued. The stock's GF Value™ is kr23.96, compared to a current price of kr14.95 — trading 37.6% below its estimated fair value. The current Return-on-Tangible-Asset is -1.83%. Mentice AB's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Mentice AB (OSTO:MNTC), the current Return-on-Tangible-Asset is -1.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mentice AB (OSTO:MNTC) Overvalued in 2026?

Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued. The current stock price of kr14.95 is trading 37.6% below its estimated GF Value™ of kr23.96. GuruFocus considers Mentice AB to be Significantly Undervalued.

Key valuation signals for OSTO:MNTC:

  • Return-on-Tangible-Asset: -1.83%
  • GF Value™: kr23.96 vs. price of kr14.95 (37.6% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the OSTO:MNTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mentice AB Business Description

Other Exchanges MN2:Germany
Address Odinsgatan 10, Gothenburg, SWE, 411 03
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
72GF Score

Get the complete analysis for OSTO:MNTC

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr14.95
Price
kr23.96
GF Value